RankAlpha logo
Back to Rankings

SNSE

Sensei BiotherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The acquisition of Faeth and the new capital give Sensei a real clinical path for PIKTOR, and the company has already moved the breast-cancer program into Phase 1b/2 while keeping the endometrial Phase 2 readout on deck. A credible data signal in either setting could re-rate the stock quickly.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.6.
What can break
1Q26 results were distorted by a $133.0 million acquired in-process R&D charge from the Faeth transaction, so reported losses are not a clean operating read on the combined company [#10-Q-2026-05-15].
Momentum
98
Value
41
Sentiment
2
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $25.00 · Bear $1.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $4.50
Why
Momentum98 · Δ7d -0.6
Value41 · Δ7d -17.5
Sentiment2 · Δ7d +5.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
98
34% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-1.6
Value
41
32% active weight
Current posture
7d trendSoftening
Δ7d
-17.5
Δ21d
+0.2
Sentiment
2
33% active weight
Current posture
7d trendImproving
Δ7d
+5.7
Δ21d
-0.7
Why this grade

Composite grade D. Momentum 98.1 / Value 41.1 / Sentiment 1.9

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$26.56M
Beta
0.28
Shares Out
1.26M
P/E (TTM) · Derived
-0.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.18
Rev YoY
-
EPS YoY
+37.2%
Gross Margin
-
Op Margin
-
Net Debt
-$40.51M
Current Ratio
5.81
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology